Washington, DC – New findings by Friends of Cancer Research (Friends) and collaborators were presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), “Agreement Across 10 Artificial Intelligence Models in Assessing HER2 in Breast Cancer Whole Slide Images: Findings from the Friends of Cancer Research Digital PATH Project.”
The poster presented the agreement of HER2 biomarker assessment across independently developed computational pathology models. These preliminary findings suggest that the level of agreement of predicted HER2 scores across models is similar to published agreement measures across pathologists. Access the poster here.
“It is crucial to have accurate and consistent identification of patients who may benefit from targeted therapies such as antibody-drug conjugates (ADCs),” said Dr. Brittany Avin McKelvey, Director of Regulatory Affairs at Friends. “The Digital PATH Project’s unique collaborative approach enables us to explore the potential of AI models to deliver more quantitative and reproducible biomarker assessments and helps address the current lack of large-scale comparative evaluations of performance.”
The Digital PATH Project launched in February 2024. Full project findings will be shared at Friends’ public meeting, “Advancing the Future of Diagnostics and Regulatory Innovations” on February 4, 2025. Click here to learn more about the meeting and register.
This partnership enables a greater understanding of the variability across AI-based models under development and supports establishing best practices for measuring and reporting AI-driven biomarker assessments in drug development and clinical practice.
Learn more about Friends Digital PATH Project and our partners here.
Authors
Brittany McKelvey, Pedro A. Torres-Saavedra, Jessica Li, Glenn Broeckx, Frederik Deman, Siraj Ali, Hillary Andrews, Salim Arslan, Santhosh Balasubramanian, J. Carl Barrett, Peter Caie, Ming Chen, Daniel Cohen, Tathagata Dasgupta, Brandon Gallas, George Green, Mark Gustavson, Sarah Hersey, Ana Hidalgo-Sastre, Shahanawaz Jiwani, Wonkyung Jung, Kimary Kulig, Vladimir Kushnarev, Xiaoxian Li, Meredith Lodge, Joan Mancuso, Mike Montalto, Satabhisa Mukhopadhyay, Matthew Oberley, Pahini Pandya, Oscar Puig, Edward Richardson, Alexander Sarachakov, Or Shaked, Mark Stewart, Lisa M. McShane, Roberto Salgado, Jeff Allen.
Partners
Friends of Cancer Research (Friends), Division of Cancer Treatment and Diagnosis, National Cancer Institute, ZAS Hospital, Lunit, Panakeia, PathAI, University of North Carolina at Chapel Hill, Indica Labs, Caris Life Sciences, GlaxoSmithKline, 4D Path, U.S. Food and Drug Administration, GA Green Consulting LLC, AstraZeneca, Bristol Myers Squibb, Molecular Characterization Laboratory at Frederick National Lab, National Cancer Institute, Kulig Consulting, BostonGene, Emory University, Amgen, Nucleai, Merck & Co., Inc.
